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Evidence of recent parvovirus virus infection (as de-
termined by the presence of a positive IgM antibody 
titer) without other identified C8uaes of anemia was 
found in 5 of 26 pediatric solid-organ tr8D8Plant recip-
ients evaluated for moderate-to-severe anemia between 
June 1990 and July 1991. Anemia tended to be chronic 
(median duration of anemia at the time of diagnosis was 
12 weeka) and was usociated with normal red blood cell 
indices in the absence of reticulocytes. The median age 
of the children at the time of presentation with anemia 
due to parvovirus was 1.8 years at a median time of 8 
months after transplantation. Four of the 5 children 
were treated with i. v. immunOilobulin becauae of per-
si8tance of anemia requiring blood transfusions. A re-
spoue characterized by an increase in reticulocyte 
count and normalization of hemoglobin was seen in each 
of these patients 2-4 weeks after treatment. The re-
maining patient experienced a 8pOntaneou8 recovery 
from her anemia. Parvovirus infection should be in-
cluded in the differential diagn08is of solid-organ trans-
plant recipients presenting with severe anemia B880Ci-
ated with low or absent reticulocytes. 
Human parvovirus B19 has been identified as the cause of 
erythema infecti08um (Fifth's Diseue) in children (1-3). In-
fection with this virus has resulted in the development of red 
cell aplasia in patients with underlying hemolytic anemias 
(including sickle cell disease, hemoglobin SC disease, hereditary 
spherocytosis. thalassemia. pyruvate kinase deficiency, and ac-
quired hemolytic anaemia) (4-10). Persistent anemia associ-
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ated with chronic parvovirus B19 infection has been reported 
in the absence of pre-existing hemolytic tendencies in immu-
nocompromised patients including those with acute leukemia, 
congenital immunodeficiencies, and HIV infection and in re-
cipients of bone marrow transplantation (11-20). This report 
documents our experience in 5 pediatric solid-organ transplant 
recipients with severe anemia associated with active parvovirus 
B19 infection. 
MATERIALS AND METHODS 
Between June 1990 and July 1991, 26 children who had received 
solid organ transplants at the Children', Hoepital of Pittsburgh were 
inveetipted for the etiology of moderate-to-eevere anemia. The evalu· 
ation included. a complete blood count, reticulocyte count, haptoglobin 
and free hemoglobin level, iron ,tudies (eerum iron, total iron binding 
capacity, and aaturetion), eerum folate and B12 levels, 8tool hemateat, 
and meuurement of blood urea nitrogen and eerum creatinine. Addi-
tionally, all patients had eeroiogic 'tudies performed for the prnence 
of antibody against CMV. EBV, and parvovirua B19. Some of the 
patienta alao underwent bone marrow upiration. 
All patienta were immunOluppreued. in a standardized. fuhion with 
either a combination of CIA, steroids, and AZA (21 ) or FK·506 (21). 
IgG and IgM antibodies against parvovirua B19 were determined. by 
a commercial laboratory (Specialty Laboratories, Inc., Santa Monica, 
CAl utilizing Western blot analyaia in all but 2 of the patienta who 
were evaluated by enzyme immune .... y (Nichola Institute Reference 
Laboretory, San Juan Capistrano, CAl. A positive IgG titer wu con-
sidered to be additional support for this diagnoail. Patients who had a 
poaitive IgG titer in the absence of IgM were considered to have put 
infection and were not included. 
RESULTS 
Five of 26 patients (23 liver and 3 heart transplant recipients) 
evaluated for anemia were found to have serologic evidence of 
recent parvovirus B19 infection without other identified causes 
of anemia. IgM antibody studies were negative in the remaining 
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21 children undergoing evaluation. Four of the 5 patients were 
positive for both IgM and IgG at the time of evaluation. Patient 
4 was initially positive for IgM only but on follow-up testing 2 
months later was found to be seropositive for IgG and negative 
for IgM. Table 1 outlines the clinical course and outcome of 
these children. The median age of the children at the time of 
presentation with anemia due to parvovirus was 1.8 years t range 
of 1.4 to 4.7 years). The median time that anemia was first 
noted after transplantation was 8 months (range of 2 to 34 
months). The median duration of anemia at the time of diag-
nosis was 12 weeks (range of 4 to 14 weeks). 
The clinical presentation of parvovirus BI9 was limited to 
severe anemia associated with reticuiocytopenia in 4 of the 5 
patients. Patient 1 presented with a typical rash of erythema 
infectiosum. 
None of the 5 patients had any history of an underlying 
hemolytic anemia. All had normal RBC indices with slight 
hypochromia and anisocytosis without hemolysis on evaluation 
of peripheral blood smears. Reticulocytes were absent despite 
severe anemia in 4 of the 5 children; the remaining child had a 
reticulocyte count of less than 1 %. White blood cell counts 
were decreased in 2 of the patients; patient 4 had an absolute 
neutrophil count of 520 cells/mm3 during his admission with 
fever and croup. Platelet counts. as well as serum levels of 
erythropoietin. haptoglobin. iron. TIBC. folate. and B12. were 
normal in all cases. Bone marrow biopsies performed on 3 
children revealed erythroid hypoplasia. One of the 3 biopsies 
was available for retrospective review and revealed the presence 
of pronormoblasts. 
All of the children were initially treated unaucceasfully with 
iron. Four children required one or more blood transfusions; 
patient 1 received a total of 11 transfusions during her illness. 
Patient 3 was unique in that anemia and areticulocytosis ap-
peared to be self-limited. Both her hemoglobin and reticulocyte 
count were recovering by the time the results of her serologies 
became available. All of the remaining children were treated 
with i.v. immunoglobulin (lVIG)* (see Table 1). A response 
characterized by an increase in reticulocyte counts and nor-
malization of hemoglobin and hematocrit levels was seen in 
each of the treated patients between 2 and 4 weeks after 
treatment. Long-term recovery from anemia has been sustained 
in these patients (follow-up greater than 1 year). 
DISCUSSION 
Human parvovirus B19 was initially discovered in 1975 and 
was recognized as the primary etiologic agent of erythema 
infectiosum (Fifth disease) in 1980 (I). The recent availability 
of serologic tests for and the ability to detect DNA ofparvovirus 
BI9 has led to the recognition of an expanding spectrum of 
clinical disease associated with infection by this virus. The 
clinical manifestations of parvovirus Bl9 infection appear to 
vary according to underlying host factors. Its propensity to 
infect and lyse red cell progenitors explains the development 
of red cell aplasia in patients with shortened red cell life spans. 
Chronic parvovirus BI9 infection has led to red cell aplasia in 
immunocompromised patients in the absence of underlying 
hemolytic anemia (11-20). This has been reported in a child 
* Abbreviations: IVIG. i.v. immunoglobin. 
TABLE 1. General description of pediatnc transplant recipients with parvovirus 8-19 infection 
Onset 
of ane· Lowest Duration of 
Patient Age Sel Type Immune mia Hgb Reticulocyte Signs & anemia prior to (yr) TX suppression after (gm! count symptoms treatment Treatment Outcome 
TX dI) (wk) 
(mo) 
1.8 F Liver FK·506 2 4.6 0 Erythema in- 14 Iron & folic acid Hb normalized 
fectio8um IVIG 1 gm/kg x with good 
3 days retic count 4 
wk after 
IVIG 
2 4.7 F Liver CyA 34 7.3 0.4 None 12 IVIG 400 mg/kg x Hb normalized 
10 days; repeat with good 
every 2 wk for 6 retic count 2 
mo wk after 
IVIG 
3 1.8 F Heart FK-506 8 5.4 0 None N/A Iron. erythropoetin Hbimproveci 
with good 
retic count 




4 1.4 M Liver FK-506 6 6.9 0 Fever. stridor 10 Iron IVIG 400 mg/ Hb improved 
kg x 5 days. with good 
GCSF retic count 4 
wk after 
IVIG 
5 1.4 M Liver FK-506 8 7.0 0.8 None 12 Iron IVIG 400 mg/ Hb improved 
kg x 5 days with good 
retic count 
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with Nezelofs syndrome (11), in patients with leukemia or 
cancer receiving maintenance chemotherapy (13-16), bone-
marrow transplant recipients (17), and in patients infected 
with HIV (18-19). Children undergoing solid-organ transplan-
tation are also at risk of red cell aplasia due to parvovirus BI9 
infection. 
The observation that a parvovirus induced red cell aplasia 
crisis can occur in pediatric solid-organ transplant recipients 
has important implications. Seroprevalence studies have esti-
mated that 30-70% of all adults show serologic evidence of past 
infection. Antibody is most commonly acquired between 5 and 
15 years of age (2). Therefore, young children who have under-
gone solid-organ transplantation seem likely to experience in-
fection with parvovirus B19 while receiving chronic immuno-
suppressive therapy. Since the reports to date suggest that red-
cell aplasia is seen in patients experiencing primary infection, 
these young (and presumably seronegative) transplant recipi-
ents may be at a relatively high risk of developing this compli-
cation. 
The actual incidence of parvovirus BI9-associated anemia 
in pediatric solid-organ transplant recipients is unknown. Ane-
mia is a relatively common occurrence in these patients, and 
the systematic work-up for this problem may vary from one 
transplant center to another. Recognition of parvovirus BI9 as 
a potential etiology in patients with chronic anemia prompted 
our evaluation of these children. Several reports have docu-
mented the presence of parvovirus DNA in serum of patients 
in the absence of detectable antibody (14, 16, 19, 20). This 
suggests that the diagnosis may be missed (especially in an 
immunosuppressed population) if only antibody levels are 
measured. Therefore, several investigators have suggested the 
use of polymerase chain reaction, dot-blot hybridization, or 
other assays to look for direct evidence of the virus rather than 
relying on host immune response for diagnosis (18,19). 
Some authors have suggested that the diagnosis of parvovirus 
BI9 can has also be made by evaluation of bone marrow 
specimens. Infection is suggested by the presence of giant 
pronormoblasts on bone marrow smears (12) or electron mi-
crographs (22). The finding of a readily identifiable intranu-
clear inclusion limited to erythroid line cells on air-dried, 
formalin-fiXed bone marrow smears stained with hematoxylin-
eosin or Wright-Giemsa has been suggested as a rapid and 
sensitive method of identifying parvovirus B19 infection (23). 
This finding was found retrospectively in the only bone marrow 
biopsy available for review from these patients. The utility of 
this finding as a screen for parvovirus infection in organ-
transplant recipients remains to be validated. 
Infection in immunologically normal individuals results in a 
relatively short period of viremia followed by the production of 
lpecific neutralizing antibodies resulting in protection of eryth-
roid progenitor cells and clearance of infection (24). Persistence 
of infection has been noted in the absence of an adequate 
antibody response (18), placing immunosuppressed patients 
(including transplant recipients) at risk for chronic infection. 
The chronicity and severity of anemia in immunodeficient 
patients may in part be due to the presence of chronic infection 
with persistent lysis of erythrocyte progenitors in the bone 
marrow in combination with the normal destruction of periph-
eral red blood cells with aging (16). 
All of our patients presented with severe anemia. IVIG (0.4 
elkg for 5 days) has been suggested for immunosuppressed 
patients with chronic anemia caused by parvovirus based upon 
laboratory and anecdotal clinical experience (12-14, 18-20,25). 
Four patients were treated with varying regimens of IVIG; all 
had an apparent clinical response shortly after completion of 
their therapy. Although the lack of a controlled study evaluating 
the use of IVIG for these patients raises doubt as to whether 
the observed clinical response might have occurred sponta-
neously, the coincidental timing of the clinical response to 
IVIG treatment in our patients (and in the literature) suggests 
the likely efficacy of this treatment. 
Patient 3 was unique in that she did not require blood 
transfusion and she experienced a spontaneous recovery of her 
bone marrow beginning 4 weeks after initial presentation. Her 
clinical course illustrates the potential variability in the effects 
of parvovirus infections in transplant recipients with recog-
nized anemia. IVIG therapy may only be necessary in those 
patients with evidence of chronic infection requiring one or 
more blood transfusions. 
Parvovirus infection should be included in the differential 
diagnosis of solid-organ transplant recipients presenting with 
severe anemia and low or absent reticulocytes. While specific 
antiviral therapy is not currently available and some patients 
may spontaneously recover, IVIG does appear to be efficacious 
and safe. Further studies on parvovirus prevalence, spectrum 
of disease, and role of treatment with IVIG in this population 
of children are warranted. 
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FATE OF RENAL ALLOGRAFTS TRANSPLANTED IN PATIENTS 
WITH URINARY DIVERSION 
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Fifty-five kidneys were transplanted into 50 patients 
with supravesical urinary diversion at 16 transplant 
centers between 1970 and 1991. Of the 32 males and 
18 females, 40 were adults (::!18 years) and 10 were less 
than 18 years old at the time of first transplant. Mean 
follow-up was 7.8 years. At last follow-up, 94% of re-
cipients were alive and 73% of the kidneys were func-
tioning. Fifteen kidneys were lost: 9 to rejection, 3 to 
noncompliance. and 3 patients died with a functioning 
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kidney. Ten (l8o/c) transplants were followed by sur-
gical complications. Twenty-four (44%) were followed 
by medical complications of which urinary tract infec-
tion was most common. Recipients age 18 or younger 
had more urinary tract infections than older patients. 
No patient had urinary stones and no patient required 
medical treatment for metabolic abnormalities. We con-
clude that drainage of kidney transplants into a su-
pravesical urinary diversion is an effective treatment 
for end-stage renal diseue patients without adequate 
urinary bladders. i 
In 1966 Kelly, Merkel. and Markland (J) first reported the " 
use of intestinal conduits for drainage of transplant kidneys. 
In their pioneering series of 8 kidneys transplanted into 7 '. 
patients. half were functioning at up to 10 months follow-up. i 
Three of 7 patients died of sepsis in the perioperative period .. 
and 1 patient had a small bowel obstruction. In the 19708. ' 
reports of long-term follow-up of patients with ileal conduit 
urinary diversion documented an increased risk of stomal ste-
nosis. acute and chronic pyelonephritis. renal scarring, renal 
failure. calculi. and metabolic alterations in patients with uri-
nary diversion (2). Despite concerns about complicationa, 
